Log in
(Ad)
If you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks.

NASDAQ:XLRN - Acceleron Pharma Stock Price, Forecast & News

$52.99
-1.10 (-2.03 %)
(As of 01/23/2020 07:25 AM ET)
Today's Range
$52.87
Now: $52.99
$55.47
50-Day Range
$48.68
MA: $52.22
$56.24
52-Week Range
$37.01
Now: $52.99
$56.90
Volume804,096 shs
Average Volume340,365 shs
Market Capitalization$2.81 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.25
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XLRN
CUSIPN/A
Phone617-649-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.99 million
Book Value$6.32 per share

Profitability

Net Income$-118,870,000.00
Net Margins-353.57%

Miscellaneous

Employees173
Market Cap$2.81 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive XLRN News and Ratings via Email

Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc (NASDAQ:XLRN) posted its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.83) by $0.03. The biopharmaceutical company had revenue of $4.20 million for the quarter, compared to analysts' expectations of $4.44 million. Acceleron Pharma had a negative return on equity of 30.79% and a negative net margin of 353.57%. The firm's quarterly revenue was up 27.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.63) earnings per share. View Acceleron Pharma's Earnings History.

When is Acceleron Pharma's next earnings date?

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Acceleron Pharma.

What price target have analysts set for XLRN?

12 equities research analysts have issued 1 year target prices for Acceleron Pharma's stock. Their forecasts range from $45.00 to $88.00. On average, they expect Acceleron Pharma's share price to reach $62.91 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.

What is the consensus analysts' recommendation for Acceleron Pharma?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.

What are Wall Street analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:
  • 1. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (1/16/2020)
  • 2. HC Wainwright analysts commented, "We are lowering our price target to $68 from $69 due to the discontinuation of ACE-083 for FSHD. Our $68 price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline, and estimated year-end cash." (9/17/2019)

Has Acceleron Pharma been receiving favorable news coverage?

News headlines about XLRN stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acceleron Pharma earned a news impact score of -1.3 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Acceleron Pharma.

Are investors shorting Acceleron Pharma?

Acceleron Pharma saw a decrease in short interest in December. As of December 13th, there was short interest totalling 4,230,000 shares, a decrease of 6.8% from the November 28th total of 4,540,000 shares. Based on an average daily trading volume, of 359,500 shares, the short-interest ratio is presently 11.8 days. Currently, 9.4% of the company's stock are short sold. View Acceleron Pharma's Current Options Chain.

Who are some of Acceleron Pharma's key competitors?

What other stocks do shareholders of Acceleron Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Cisco Systems (CSCO), Gilead Sciences (Gild), LogicBio Therapeutics (LOGC), Intercept Pharmaceuticals (ICPT), Incyte (Incy), Corcept Therapeutics (CORT), Exelixis (EXEL), Intel (INTC) and Bausch Health Companies (BHC).

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the folowing people:
  • Mr. Habib J. Dable, CEO, Pres & Director (Age 50)
  • Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 76)
  • Mr. Kevin F. McLaughlin, Sr. VP, CFO & Treasurer (Age 63)
  • Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 59)
  • Dr. John D. Quisel, Exec. VP, Chief Bus. Officer & Sec. (Age 48)

Who are Acceleron Pharma's major shareholders?

Acceleron Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.91%), Rhenman & Partners Asset Management AB (0.19%), Neville Rodie & Shaw Inc. (0.04%), Wealthstreet Investment Advisors LLC (0.04%), Zeke Capital Advisors LLC (0.02%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops and Sujay Kango. View Institutional Ownership Trends for Acceleron Pharma.

Which institutional investors are selling Acceleron Pharma stock?

XLRN stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Neville Rodie & Shaw Inc., Zeke Capital Advisors LLC, Nisa Investment Advisors LLC and Wealthstreet Investment Advisors LLC. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin, Ravindra Kumar and Sujay Kango. View Insider Buying and Selling for Acceleron Pharma.

Which institutional investors are buying Acceleron Pharma stock?

XLRN stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

How do I buy shares of Acceleron Pharma?

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $52.99.

How big of a company is Acceleron Pharma?

Acceleron Pharma has a market capitalization of $2.81 billion and generates $13.99 million in revenue each year. The biopharmaceutical company earns $-118,870,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.View Additional Information About Acceleron Pharma.

What is Acceleron Pharma's official website?

The official website for Acceleron Pharma is http://www.acceleronpharma.com/.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]


MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  492 (Vote Outperform)
Underperform Votes:  354 (Vote Underperform)
Total Votes:  846
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: Hedge Funds Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel